1. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors

   • Nick Bosanquet
   • Bengt Jönsson
   • Keith A. A. Fox

   Original Research Article 22 September 2012 Pages: 1135 - 1152

   

2. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer

   • Silas C. Martin
   • Dennis D. Gagnon
   • Ben van Hout

   Original Research Article 22 September 2012 Pages: 1153 - 1169

   

3. The cost effectiveness of Apligraf® treatment of diabetic foot ulcers

   • W. Ken Redekop
   • Joseph McDonnell
   • Zoltan Kalo

   Original Research Article 22 September 2012 Pages: 1171 - 1183

   

4. Escitalopram

   • Katherine F. Croom
   • Greg L. Plosker

   Original Research Article 22 September 2012 Pages: 1185 - 1209

   

5. Pharmaceutical expenditure and therapeutic value of new medicines in Spain

   • Josep Darba

   Correspondence 22 September 2012 Pages: 1211 - 1212